‘Phase 2 trials almost completed’: Dr Krishna Ella on nasal Covid-19 vaccine

The vaccine has shown ‘good results,’ the Bharat Biotech chairman and MD said, echoing Dr VK Paul's remarks from last month.
A health worker collects swab samples for Covid-19 tests in Nagpur, Maharashtra. (PTI)
A health worker collects swab samples for Covid-19 tests in Nagpur, Maharashtra. (PTI)
Published on Oct 23, 2021 04:06 PM IST
Copy Link
Byhindustantimes.com, New Delhi

The phase 2 trials of Bharat Biotech International Limited’s nasal vaccine against the coronavirus disease (Covid-19) are almost over, Dr Krishna Ella, the Hyderabad-based firm’s chairman and MD, said on Saturday, as he congratulated the country on achieving the feat of administering more than 1 billion or 100 crore doses of Covid-19 vaccines. “We’ve almost completed the phase 2 trials for the nasal vaccine, and it has shown good results. It will help in controlling the transmission of the infection,” Dr Ella said, according to news agency ANI.


The vaccine, BBV154, received regulatory approvals for phase 2/3 trials in August, thus becoming the first-of-its-kind Covid-19 jab to undergo human testing in the country. The internasal jab, the development of which was supported by the Department of Biotechnology (DBT) and Biotechnology Industrial Research Assistance Council (BIRAC), underwent phase 1 testing on volunteers in the age group of 18-60, and was “well tolerated.”

Also Read | First nasal vaccine developed by Bharat Biotech gets nod for Phase 2/3 trial

Last month, Dr VK Paul, Niti Aayog member (Health), said that the findings from the vaccine’s first phase trials had been “promising.”

Also Read | Initial findings from Biotech's nasal vaccine show 'promising results': Govt

Meanwhile, speaking on Covaxin for kids, Dr Ella said that the company was still waiting for a license from the Drugs Controller General of India (DCGI) in this regard. Covaxin, the country’s first indigenously developed anti-Covid shot, which is being used in the nationwide inoculation drive, was, earlier this month, recommended by the Subject Expert Committee (SEC) for the age group of 2-18.

Also Read | DCGI yet to approve Covaxin’s emergency use in children

Before Covaxin, Ahmedabad-based Zydus Cadilla’s ZyCoV-2 received emergency use authorisation (EUA) for an age group below 18, being approved for everyone aged 12 and above. The nationwide vaccination drive, which began on January 16, is currently open only for citizens who are 18-years-old and above.

Also Read | Bharat Biotech’s Covaxin gets emergency approval for kids aged 2-18 years

On Thursday, India crossed the milestone of administering more than a billion doses of Covid-19 jabs. The figure includes both single and fully (double) vaccinated beneficiaries.


Close Story
Story Saved
Saved Articles
My Reads
Sign out
New Delhi 0C
Monday, November 29, 2021